Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 205-206, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gagajewski, A.
Right arrow Articles by Apple, F. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gagajewski, A.
Right arrow Articles by Apple, F. S.
Related Collections
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2002;48:205-206.)
© 2002 American Association for Clinical Chemistry, Inc.

Letters

False-Positive Lysergic Acid Diethylamide Immunoassay Screen Associated with Fentanyl Medication

Angelique Gagajewski1, Gershwin K. Davis1, Julie Kloss1, Gregory K. Poch2, Cynthia J. Anderson2 and Fred S. Apple1a

1 Hennepin County Medical Center, Clinical Laboratories MC 812, 701 Park Ave., Minneapolis, MN 55415

2 Navy Drug Screening Laboratory, San Diego, CA 92134

aAuthor for correspondence. Fax 612-904-4229; e-mail fred.apple@co.hennepin.mn.us.


To the Editor:

The prevalence of lysergic acid diethylamide (LSD) use has steadily increased over the past two decades. The 2000 National Household Survey on Drug Abuse (1) estimated that of the population 12 years and older, 3.5% have tried LSD. With the increase in LSD and other illicit drug use, urine drug screening in occupational and clinical settings has likewise increased. In the toxicology laboratory of Hennepin County Medical Center, LSD is one of eight drugs screened in the routine urine immunoassay drugs-of-abuse panel. In this report, we describe several cases involving false-positive urine screens for LSD by either the CEDIA and/or SYVA Emit II immunoassays. In one case, two urine samples that were immunoassay positive for LSD failed to confirm either LSD or its metabolite 2-oxo-3-hydroxy LSD by liquid chromatography-mass spectrometry (LC-MS).

The case involved a 31-year-old male with severe end-stage cardiomyopathy secondary to rheumatic heart disease and crack cocaine abuse. He called emergency medical services from home with complaints of shortness of breath. He was subsequently diagnosed with cardiogenic shock secondary to sepsis and cardiomyopathy. He was intubated and admitted to the coronary care unit for hemodynamic support including intraaortic balloon pump. His initial urine drug screen on admission was negative.

The patient was treated for sepsis and gradually weaned from ventilatory and pressor support. The patient’s condition steadily improved. While in . . . [Full Text of this Article]


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.